Streetbeat News

Stock Prices

HP

Barclays analyst David Anderson has downgraded Helmerich & Payne (NYSE:HP) from Overweight to Equal-Weight and reduced the price target from $44 to $40.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 11:48 am

NAVI

Barclays analyst Mark Devries has downgraded Navient (NASDAQ:NAVI) from Equal-Weight to Underweight and reduced the price target from $17 to $14.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 11:46 am

DTC

Citigroup analyst Wendy Nicholson has downgraded Solo Brands (NYSE:DTC) from Buy to Neutral and reduced the price target from $10 to $4.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 11:43 am

PIII

P3 Health Partners Inc (NASDAQ:PIII) shares rose approximately 10% after the company reaffirmed its 2023 guidance and provided a positive outlook for 2024, with expected revenue and Adjusted EBITDA surpassing consensus estimates. The company anticipates growth in Medicare Advantage Members and Medical Margin. William Blair analyst Ryan Daniels reaffirmed an Outperform rating, citing strong organic growth prospects, positive macro tailwinds, and a scalable business model.

Portfolio Pulse from Lekha Gupta

January 10, 2024 | 11:43 am

LLY

NVO

Novo Nordisk CEO Lars Fruergaard Jorgensen expressed optimism about the prolonged patient adherence to the obesity drug Wegovy at the JPMorgan Healthcare conference. He cited data showing a 40% adherence rate after a year, surpassing older medications. Novo Nordisk and Eli Lilly are leaders in the weight loss drug market, which could be worth $100 billion by 2030. Jorgensen welcomed competition and mentioned the approval of Eli Lilly's Zepbound. Novo Nordisk is also exploring oral treatments, with a once-daily weight-loss pill showing promise in trials. NVO shares saw a slight increase in premarket trading.

Portfolio Pulse from Vandana Singh

January 10, 2024 | 11:43 am

DTC

Jefferies analyst Randal Konik downgraded Solo Brands (NYSE:DTC) from Buy to Hold and reduced the price target from $12 to $4, indicating a more cautious outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 11:40 am

WWD

Goldman Sachs analyst Noah Poponak has upgraded Woodward (NASDAQ:WWD) from Sell to Buy and increased the price target from $105 to $153.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 11:36 am

CRERF

LVMUY

SNY

Sanofi SA (NASDAQ:SNY) is sponsoring the 2024 Olympic Games in Paris to transform its image and attract a younger workforce. The company is joining other French companies like LVMH and Carrefour in this endeavor. Sanofi's commitment includes backing athletes and involving over 8,000 employees in the Games. The financial investment is speculated to be a significant sum, though exact figures are not disclosed. The impact on investor sentiment is uncertain given Sanofi's recent financial challenges and business model changes. SNY shares closed at $51.76 on Tuesday.

Portfolio Pulse from Vandana Singh

January 10, 2024 | 11:36 am

FBRT

JMP Securities analyst Steven Delaney has upgraded Franklin BSP Realty Trust (FBRT) from Market Perform to Market Outperform and set a price target of $15.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 11:33 am

SGH

Needham analyst Quinn Bolton has reaffirmed a Buy rating on SMART Global Holdings (NASDAQ:SGH) and increased the price target from $22 to $24.

Portfolio Pulse from Benzinga Newsdesk

January 10, 2024 | 11:31 am